However, ACE inhibitors, ARBs, or aldosterone antagonists (mineralocorticoid receptor antagonists) are often used to treat HFpEF and / or associated comorbidities (such as hypertension and renal dysfunction), although survival benefit has not been demonstrated in clinical trials and, therefore, are not considered a standard of care.